{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.9","upperLimit":"650","value":"220"},{"groupId":"OG001","lowerLimit":"118","upperLimit":"483","value":"254"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Maximum observed plasma concentration (ng/mL), obtained directly from the observed concentration versus time data. Calculated for the C1D1 and C2D1 doses.","dispersionType":"Full Range","groups":[{"description":"PK Sampling on C1D1","id":"OG000","title":"C1D1"},{"description":"PK Sampling on C2D1","id":"OG001","title":"C2D1"}],"paramType":"MEDIAN","populationDescription":"PK population includes all subjects, at the selected sites in Japan and all sites in South Korea, who have pretreatment baseline and at least 1 blood sample on study providing PK data for HBI-8000.","reportingStatus":"POSTED","timeFrame":"0 (predose) up to 72 hours postdose on C1D1 and 0 (predose) up to 4 hours postdose on C2D1","title":"Pharmacokinetics (Cmax-selected Sites)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"ng/mL"}